NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03412773,Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC,https://clinicaltrials.gov/study/NCT03412773,,COMPLETED,"This is a Phase 3, randomized, open-label, multicenter, global study designed to compare the efficacy and safety of tislelizumab versus sorafenib as a first-line systemic treatment in participants with unresectable hepatocellular carcinoma. This study also includes a substudy investigating the safety, tolerability, PK, and preliminary efficacy in HCC in Japanese participants. In Japan, preliminary safety and tolerability will be evaluated (Safety Run-In Substudy) before Japanese participants are recruited in this Phase 3 study.",NO,Hepatocellular Carcinoma (HCC),DRUG: Tislelizumab|DRUG: Sorafenib,"Overall Survival (OS), From date of randomization up to 4 years, approximately|Safety Run-In Substudy[Japan only]: Percentage of participants with adverse events, From date of enrollment up to 4 years, approximately.|Safety Run-In Substudy[Japan only]: Percentage of participants with dose-limiting toxicities (DLT) [Determination of the pivotal Phase 3 dose of tislelizumab in Japanese participants], From the date of enrollment up to 28 days [DLT period].|Safety Run-In Substudy[Japan only]: Maximum Concentration (Cmax) of Tislelizumab, From first dose of study treatment up to 4 years, approximately.|Safety Run-In Substudy[Japan only]: Trough Serum Concentration (Cmin) of tislelizumab, From first dose of study treatment up to 4 years, approximately.|Safety Run-In Substudy[Japan only]: Area Under the Curve (AUC) of tislelizumab, From first dose of study treatment up to 4 years, approximately.|Safety Run-In Substudy[Japan only]:Anti-Drug Antibodies (ADA) against tislelizumab at Cmin, From first dose of study treatment up to 4 years, approximately.|Safety Run-In Substudy[Japan only]: Percentage of Participants With Clinically Significant Changes in Vital Signs Findings, From date of enrollment up to 4 years, approximately.|Safety Run-In Substudy[Japan only]: Percentage of Participants With Clinically Significant Changes in Physical Examination Findings, From date of enrollment up to 4 years, approximately.|Safety Run-In Substudy[Japan only]: Percentage of Participants With Clinically Significant Changes in Clinical Laboratory Results Findings, From date of enrollment up to 4 years, approximately.|Safety Run-In Substudy[Japan only]: Percentage of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings, From date of enrollment up to 4 years, approximately.","Objective Response Rate (ORR), From date of randomization up to 4 years, approximately|Progression-free survival (PFS), From date of randomization up to 4 years, approximately|Duration of Response (DOR), From first determination of an objective response up to 4 years, approximately|Time to Progression (TTP), From date of randomization up to 4 years, approximately.|Health-Related Quality of Life (HRQoL), From date of enrollment up to 4 years, approximately.|Disease Control Rate (DCR), From first dose of study treatment up to 4 years, approximately|Clinical Benefit Rate (CBR), From first dose of study treatment up to 4 years, approximately|Percentage of participants with adverse events, From date of screening up to 4 years, approximately.|Safety Run-In Substudy[Japan only]: Objective Response Rate (ORR), From date of randomization up to 4 years, approximately.|Safety Run-In Substudy[Japan only]: Progression-free survival (PFS), From date of randomization up 4 years, approximately|Safety Run-In Substudy[Japan only]: Duration of Response (DOR), From date of randomization up 4 years, approximately|Safety Run-In Substudy[Japan only]: Overall Survival (OS), From date of randomization up 4 years, approximately|Safety Run-In Substudy[Japan only]: Anti-tislelizumab antibody, From first dose of study treatment up 4 years, approximately|Percentage of Participants With Clinically Significant Changes in Vital Signs Findings, From date of enrollment up to 4 years, approximately|Percentage of Participants With Clinically Significant Changes in Physical Examination Findings, From date of enrollment up to 4 years, approximately|Percentage of Participants With Clinically Significant Changes in Clinical Laboratory Results Findings, From date of enrollment up to 4 years, approximately|Percentage of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings, From date of enrollment up to 4 years, approximately",,BeiGene,,ALL,"ADULT, OLDER_ADULT",PHASE3,674,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,BGB-A317-301|2017-002423-19|CTR20170882|JapicCTI-194569,2017-12-28,2022-07-11,2023-12-14,2018-01-26,,2024-01-10,"Southern California Research Center, Coronado, California, 92118, United States|St. Jude Heritage Healthcare, Fullerton, California, 92835, United States|University of California - Hematology and Oncology, Los Angeles, California, 90095, United States|Chao Family Comprehensive Cancer Center, Orange, California, 92868, United States|Inland Empire Liver Foundation, Rialto, California, 92377, United States|Ingalls Memorial Hospital, Harvey, Illinois, 60426, United States|Healthcare Research Network III, LLC, Tinley Park, Illinois, 60487, United States|Ochsner Medical Center (OMC) - New Orleans ACCRU Network Sit, New Orleans, Louisiana, 70121-2429, United States|University Medical Center New Orleans, New Orleans, Louisiana, 70121, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, 02114, United States|UMass Memorial Medical Center, Worcester, Massachusetts, 01655, United States|Umdnj-Njms, Newark, New Jersey, 07103, United States|Northwell Health/Monter Cancer Center, Lake Success, New York, 11042, United States|White Plains Hospital Center for Cancer Care - Oncology, White Plains, New York, 10601, United States|Precision Cancer Research / Dayton Physicians Network, Kettering, Ohio, 45409, United States|Hahnemann University Hospital - Gastroenterology Hepatology, Philadelphia, Pennsylvania, 19102, United States|Cancer Treatment Centers of America - Oncology, Philadelphia, Pennsylvania, 19124, United States|Vanderbilt University Medical Center (VUMC), Nashville, Tennessee, 37232, United States|The Mays Cancer Center, San Antonio, Texas, 78229, United States|The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, 233004, China|Anhui Provincial Hospital, Hefei, Anhui, 230001, China|The First Affiliated Hospital Of Anhui Medical University, Hefei, Anhui, 230022, China|Anhui Medical University - The Second Hospital, Hefei, Anhui, 230601, China|Beijing Cancer Hospital, Beijing, Beijing, 100142, China|Chinese PLA General Hospital, Beijing, Beijing, 100853, China|302 Military Hospital of China, Beijing, Beijing, China|Beijing YouAn Hospital, Capital Medical University, Beijing, Beijing, China|Cancer Hopital Chinese Academy of Medical Sciences, Beijing, Beijing, China|Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, China|Fujian Provincial Cancer Hospital, Fuzhou, Fujian, 350014, China|Guangdong General Hospital, Guangzhou, Guangdong, 510080, China|Nanfang Hospital, Guangzhou, Guangdong, 510515, China|Sun Yat-sen Memorial Hospital , Sun Yat-sen University, Guangzhou, Guangdong, China|The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China|Henan Cancer Hospital, Zhengzhou, Henan, 450008, China|Hubei Cancer Hospital, Wuhan, Hubei, 400037, China|Wuhan Union Hospital, Wuhan, Hubei, 430023, China|Nanjing Bayi Hospital, Nanjing, Jiangsu, 210002, China|Jiangsu Cancer Hospital, Nanjing, Jiangsu, 210009, China|The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China|The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China|Jilin Cancer Hospital, Changchun, Jilin, China|The First Hospital of Jilin University, Changchun, Jilin, China|The Affiliated Hospital Of Qingdao University, Qingdao, Shandong, China|Weifang People's Hospital, Weifang, Shandong, 261000, China|Shanghai Cancer Hospital of Fudan University, Shanghai, Shanghai, 200032, China|Zhongshan Hospital Fudan University, Shanghai, Shanghai, 200032, China|The First Affiliated Hospital Of XI'AN Jiaotong University, Xian, Shanxi, 710061, China|Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, Sichuan, Sichuan, 610072, China|Zhongnan Hospital of Wuhan University, Wuhan, Wuhan, 430071, China|The First Affiliated Hospital of Zhejiang University, HangZhou, Zhejiang, 310003, China|Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, 310016, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China|Peking Union Medical College Hospital, Beijing, 100730, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China|Fakultni nemocnice Brno, Brno, Brno-Mesto, 625 00, Czechia|Fakultni nemocnice Olomouc, Olomouc, 779 00, Czechia|Fakultni nemocnice v Motole, Praha 5, 150 06, Czechia|CHU Amiens-Hopital Nord - Hépato-Gastroentérologie, Somme, Amiens, 80054, France|CHU Cote De Nacre - Hepato-Gastro-Enterologie Et N, Caen, Cedex 05, Basse-Normandie, 14033, France|Hôpital Privé des Côtes d'Armor - Service oncologie, Plérin, Bretagne, 22190, France|Hopital Robert DEBRE, CHU Reims, Reims, Champagne-Ardenne, 51100, France|Hospitalier Jean Minjoz, Besançon, Franche-Comté, 25030, France|CHU de Grenoble Alpes, La Tronche, Isere, 38700, France|Bichat-Beaujon Service Inter Hospitalier De Cancerologie, Clichy Cedex, Lie-de-France, 92118, France|Hopital Paul Brousse- Aphp Hopitaux Universitairees Paris Su, Villejuif, Lie-de-France, 94800, France|CHU Nantes -hopital hotel Dieu, Nantes, Loire-Atlantique, 4400, France|CHU Saint Etienne, Rahon, Lyon, 42270, France|CHRU De Lille - Hôpital Claude Huriez, Lille, Nord, 59037, France|CHU de Nice - Hôpital de l'Archet II, Nice, Provence-Alpes-Côte-d'Azur, 3200, France|CHU Saint Eloi - Pôle Digestif, Bretagne, Rennes Cedex, France|Gustave Roussy - Medical Oncology, Villejuif, Val-de-Marne, 94805, France|Hospital of Poitiers, Poitiers, Vienne, 86021, France|Krankenhaus Nordwest gGmbH, Frankfurt/Main, Hessen, Germany|Maria Gonzalez-Carmona, Bonn, Nordrhein-Westfalen, 53105, Germany|Stefan Pluntke, Essen, Nordrhein-Westfalen, 45136, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, 40225, Germany|Medizinische Hochschule Hannover, Hannover, 30625, Germany|Universitätsklinikum Köln, Köln, 50937, Germany|Universitätsklinikum Leipzig AöR, Leipzig, 4103, Germany|Universitätsmedizin Mainz, Mainz, Germany|IRCCS Saverio De Bellis, AO Gastroenterologia, Castellana Grotte, Bari, 70013, Italy|Medical Oncology, Feltre, Belluno, Italy|PO G.Rodolico, AOU Policlinico-Vittorio Emanuele di Catania, Catania, Catani, 95123, Italy|Ospedale S.Bortolo, AULSS n.6 Vicenza, Vicenza, Veneto, Italy|Policlinico S.Orsola Malpighi, AOU di Bologna - SSD Malattie, Bologna, 40138, Italy|PO di Cremona, ASST di Cremona - Oncologia - Cremona - Radiology, Cremona, Italy|Ospedale Vito Fazzi, ASL Lecce, Lecce, 73100, Italy|AOU Policlinico di Modena, Modena, Italy|IRCCS Policlinico San Matteo, Pavia, 27100, Italy|Ist. Clinici Scientifici Maugeri - Unità Operativa di Oncologia, Pavia, 27100, Italy|Regina Elena, Istituto Nazionale dei Tumori, IFO, IRCCS, Roma, 144, Italy|PO Umberto I, AO Ordine Mauriziano, Torino, Italy|Fujita Health University Hospital, Toyoake, Aiti [Aichi], 470-1192, Japan|Ehime Prefectural Central Hospital - Gastroenterology, Matsuyama, Ehime, 790-0024, Japan|Ogaki Municipal Hospital, Ogaki, Gihu [Gifu], Japan|Hokkaido University Hospital - Gastroenterology, Sapporo, Hokkaidô [Hokkaido], 060-8648, Japan|Kanazawa University Hospital, Kanazawa-shi, Isikawa [Ishikawa], 9208641, Japan|Yokohama City University Medical Center, Yokohama, Kanagawa, 232-0024, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan|University Hospital, Kyoto Prefectural Univ of Medicine, Kyoto-shi, Kyôto [Kyoto], 602-8566, Japan|Nagasaki Medical Center, Omura, Nagasaki, 856-8562, Japan|Kinki University Hospital, Faculty of Medicine - Hematology & Clinical Oncology, Osaka-sayama, Osaka, 589-8511, Japan|Osaka University Hospital, Suita, Osaka, 565-0871, Japan|Chiba University Hospital, Chiba, Tiba [Chiba], 260-8677, Japan|Sasaki Foundation Kyoundo Hospital, Chiyoda-Ku, Tokyo, 101-0062, Japan|Nihon University Itabashi Hospital - Gastroenterological surgery, Itabashi-ku, Tôkyô [Tokyo], 173-8610, Japan|JRC Medical Center, Shibuya-ku, Tôkyô [Tokyo], 150-8935, Japan|National Center for Global Health and Medicine, Shinjuku-ku, Tôkyô [Tokyo], 162-8655, Japan|Kyushu Medical Center, Fukuoka, 810-8563, Japan|Kumamoto University Hospital, Kumamoto, 860-8556, Japan|Iwate Medical University Hospital, Morioka, Japan|Hyogo College of Medicine Hospital, Nishinomiya-shi, 663-8501, Japan|Osaka International Cancer Institute, Osaka, 541-8567, Japan|Tottori University Hospital, Tottori, 683-8504, Japan|Wakayama Medical University, Wakayama-shi, 641-8509, Japan|Osaka City General Hospital, Osaka, Ôsaka [Osaka], 534-0021, Japan|Osaka National Hospital, Osaka, Ôsaka [Osaka], 540-0006, Japan|Osaka City University Hospital, Osaka, Ôsaka [Osaka], 545-8586, Japan|Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Warszawa, Mazowieckie, 02-781, Poland|Clinical Research Center Sp. z o.o., Medic-R Sp. K., Poznan, Wielkopolskie, 60-569, Poland|Uniwersyteckie Centrum Kliniczne, Gdańsk, 80-211, Poland|Wojewodzki Szpital Specjalistyczny im. Gromkowskiego we Wroclawiu, Wroclaw, 51-149, Poland|Institut Catalá d´Oncología (I.C.O.), Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Vall d'Hebrón, Barcelona, 8035, Spain|Hospital Universitario Madrid Sanchinarro Centro integral Oncologico Clara Campal (CIOCC), Madrid, 28050, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital - Gastroenterology, Kaohsiung, Taiwan|Kaohsiung Medical University - Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Tri-Service General Hospital - Neihu Branch, New Taipei, Taiwan|China Medical University Hospital - Transplantology - Taichung, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, 705, Taiwan|Chi Mei Medical Center - YongKang, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei, 112, Taiwan|Chang Gung Medical Foundation - LinKou Chang Gung Memorial Hospital, Taipei, Taiwan|Queen Elizabeth Hospital - Clinical Reasearch, Birmingham, B152TH, United Kingdom|Royal Free Hospital London NHS Trust, London, NW3 2QG, United Kingdom|King's College Hospital NHS Foundation Trust, London, SE5 9RS, United Kingdom|The Christie NHS Foundation Trust - Oak Road Treatment Centre, Withington, M20 4BX, United Kingdom",
